|
Peptimmune is pepped up about stopping the immune system when it malfunctions. The research-stage biotechnology company is focused on developing pharmaceuticals that treat medical conditions in which the body essentially attacks itself. Peptimmune conducts research and development programs on potential drug candidates targeting autoimmune and inflammatory ailments such as Crohn's disease, multiple sclerosis, and rheumatoid arthritis. The company partners with other pharmaceutical firms in some of its drug development efforts; it also relies on venture capital investors to help fund its research.
|
| | | Contact Information | |
Address: |
64 Sidney St., Ste. 380
Cambridge, MA 02139
| | Phone: | 617-715-8000 | | Fax: | 617-661-8855 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 0.70 M | | Employees (2008): | 22 |
|
|
Key People
| | • |
Chairman:
Fredric D. Price
| | • |
President, CEO, and Director:
Thomas P. (Tom) Mathers
| | • |
Associate Director Finance and Administration:
Carole Cassidy
|
|
|
